Keyphrases
Early Breast Cancer
68%
Meta-analysis
63%
Confidence Interval
43%
Overall Survival
40%
Odds Ratio
38%
Hazard Ratio
37%
Systemic Review
34%
Breast Cancer
34%
Randomized Controlled Trial
33%
Metastatic Breast Cancer
33%
Systematic Meta-analysis
29%
Review Analysis
29%
Disease-free Survival
27%
Estrogen Receptor-positive
25%
Oncotype DX
21%
Cancer Characteristics
18%
Adverse Events
18%
Tumor
17%
U.S. Food
16%
Human Epidermal Growth Factor Receptor 2 (HER2)
16%
Clinical Trials
15%
Exosomal
15%
Chemotherapy
15%
Human Telomerase Reverse Transcriptase (hTERT)
14%
Aromatase Inhibitors
14%
Breast Cancer Patients
14%
Lung Cancer
14%
Hormone Receptor-positive
13%
Progression-free Survival
13%
Human Epidermal Growth Factor Receptor 2-negative
12%
Adjuvant Chemotherapy
12%
Tumor Characteristics
12%
Solid Tumors
11%
Recurrence Score
11%
Cancer Patients
10%
Risk Ratio
10%
Clinical Outcomes
10%
Retrospective Cohort Study
10%
Tolerability
10%
Randomized Phase III Trial
10%
Breast Cancer Treatment
10%
Clinical Entities
9%
Pneumonia
9%
Extended Adjuvant Therapy
9%
Adjuvant Endocrine Therapy
9%
Next-generation Sequencing
9%
Estrogen Exposure
9%
Immune Checkpoint Inhibitors
9%
COVID-19
9%
Granulocyte Colony-stimulating Factor (G-CSF)
9%
Medicine and Dentistry
Breast Cancer
100%
Meta-Analysis
66%
Overall Survival
39%
Malignant Neoplasm
36%
Neoplasm
34%
Systematic Review
34%
Hazard Ratio
31%
Metastatic Breast Cancer
30%
Estrogen Receptor
30%
Randomized Controlled Trial
29%
Odds Ratio
29%
Disease
26%
Disease Free Survival
25%
Gamma Urogastrone
23%
Epidermal Growth Factor Receptor 2
23%
Recurrent Disease
21%
Clinical Trial
20%
Cancer
16%
Adverse Event
15%
Lung Cancer
15%
Hormone Receptor
15%
Telomerase Reverse Transcriptase
14%
Aromatase Inhibitor
14%
Adjuvant Chemotherapy
14%
Smoking
13%
Progression Free Survival
11%
Adjuvant Therapy
11%
Triple Negative Breast Cancer
10%
Targeted Therapy
10%
Cohort Analysis
10%
Oncotype DX
10%
Cross Sectional Study
9%
Colorectal Cancer
9%
Next Generation Sequencing
9%
Immune Checkpoint Inhibitor
9%
Adjuvant Endocrine Therapy
9%
Neoadjuvant Chemotherapy
9%
COVID-19
8%
Lymphovascular Invasion
8%
Group Therapy
7%
Dose Densification
7%
Exosome
7%
Telomerase
7%
Cancer Diagnosis
6%
Observational Study
6%
Progesterone Receptor
6%
Postmenopause
6%
Tumor Cell
6%
Radiation Therapy
5%
Adenocarcinoma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
83%
Randomized Controlled Trial
43%
Chemotherapy
39%
Malignant Neoplasm
36%
Overall Survival
35%
Metastatic Breast Cancer
31%
Neoplasm
30%
Estrogen Receptor
29%
Disease Free Survival
24%
Adverse Event
23%
Disease
23%
Clinical Trial
22%
Epidermal Growth Factor Receptor 2
20%
Gamma Urogastrone
20%
Cohort Study
18%
Recurrent Disease
18%
Lung Cancer
16%
Telomerase Reverse Transcriptase
14%
Aromatase Inhibitor
14%
Progression Free Survival
14%
Solid Malignant Neoplasm
11%
Endocrine Therapy
11%
Triple Negative Breast Cancer
10%
Tolerability
10%
Cross-Sectional Study
9%
Trastuzumab
9%
Cyclophosphamide
8%
Granulocyte Colony Stimulating Factor
8%
Syndrome
7%
Telomerase
7%
Docetaxel
6%
Metastasis
6%
Progesterone Receptor
6%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
6%
Hormone Receptor
6%
Tumor Marker
5%
Cancer Incidence
5%
Paclitaxel
5%